PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Revenues Beat; Offers 2Q EPS Below Consensus, 2Q Revs. Above Views, Withdraws FY20 Outlook

Go back to PRA Health Sciences (PRAH) Tops Q1 EPS by 4c, Revenues Beat; Offers 2Q EPS Below Consensus, 2Q Revs. Above Views, Withdraws FY20 Outlook

PRA Health Sciences, Inc. Reports First Quarter 2020 Results, Withdraws Full Year 2020 Guidance Due to Uncertain COVID-19 Impact and Provides Second Quarter 2020 Guidance

April 30, 2020 4:02 PM EDT

Net new business of $604.7 million; Net book-to-bill of 1.10 excluding reimbursement revenueNet new business of $955.9 million; Net book-to-bill of 1.32 including reimbursement revenue$783.7 million of total revenue; representing 8.5% growth at actual foreign exchange rates and 9.3% growth on a constant currency basisGAAP net income per diluted share of $0.63 and GAAP net income of $40.7 millionAdjusted net income per diluted share was $1.05 and adjusted net income was $67.3 millionWithdrawing full year 2020 guidance due to the uncertainty around the impact of the COVID-19 pandemic on... More